Floatz logo

Galcanezumab

Overactive Bladder

The Cleveland Clinicmonoclonal_antibodyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Overactive Bladder cohort.

Asset / SponsorPhaseRating
Mirabegron
VA Office of Research and Development
Phase 4BB
TROSPIUM
Allergan
Phase 4BB
Nabiximols
Jazz Pharmaceuticals
Phase 3BB
SOLIFENACIN
VA Office of Research and Development
Phase 4B
Oxybutynin
University of California, Davis
Phase 3B

View all 22 →

Same molecule, other indications

Galcanezumab is also rated in:

migraine disorderDormant
BBB
Indicative ·
78 / 100
View asset →
glossopharyngeal neuralgiaDormant
BB
Indicative ·
69 / 100
View asset →
migraine disorderDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →